Table 3.
AUROC analyses of the discriminatory ability of extracellular matrix markers for detecting advanced disease.
| Test panel |
Validation panel |
||||
|---|---|---|---|---|---|
| PSC |
PBC |
AIH |
PSC |
PSC |
|
| LSM∗ | LSM∗ | LSM∗ | Mayo | Mayo | |
| N advanced/total (%) | 37/70 (53) | 25/68 (37) | 17/52 (33) | 30/78 (38) | 68/129 (53) |
| PRO-C3/C3M | 0.830 (0.727, 0.933) p <0.001 |
0.767 (0.641, 0.892) p <0.001 |
0.585 (0.415, 0.755) p = 0.33 |
0.761 (0.656, 0.866) p <0.001 |
0.772 (0.692, 0.853) p <0.001 |
| PRO-C3 | 0.855 (0.766, 0.944) p <0.001 |
0.833 (0.722, 0.943) p <0.001 |
0.771 (0.641, 0.900) p <0.001 |
0.820 (0.727, 0.913) p <0.001 |
0.826 (0.754, 0.898) p <0.001 |
| PRO-C5 | 0.498 (0.360, 0.636) p = 0.98 |
0.643 (0.505, 0.781) p = 0.04 |
0.676 (0.529, 0.823) p = 0.02 |
0.655 (0.524, 0.786) p = 0.02 |
0.721 (0.633, 0.809) p <0.001 |
| C3M | 0.620 (0.488, 0.752) p = 0.09 |
0.673 (0.540, 0.807) p = 0.01 |
0.708 (0.566, 0.850) p = 0.004 |
0.681 (0.551, 0.810) p = 0.01 |
0.716 (0.628, 0.804) p <0.001 |
| C4M | 0.510 (0.373, 0.647) p = 0.88 |
0.668 (0.533, 0.804) p = 0.02 |
0.708 (0.561, 0.855) p = 0.01 |
0.644 (0.511, 0.776) p = 0.03 |
0.761 (0.679, 0.843) p <0.001 |
| BGM | 0.419 (0.284, 0.553) p = 0.24 |
0.644 (0.509, 0.780) p = 0.04 |
0.548 (0.377, 0.719) p = 0.58 | 0.535 (0.398, 0.673) p = 0.62 | 0.606 (0.507, 0.704) p = 0.04 |
| VICM | 0.470 (0.331, 0.609) p = 0.67 |
0.280 (0.149, 0.411) p = 0.001 |
0.339 (0.171, 0.506) p = 0.06 |
0.488 (0.357, 0.618) p = 0.85 |
0.504 (0.404, 0.605) p = 0.93 |
∗
For analyses involving LSM: panel restricted to patients with LSM available and AST <175. Published cut-off levels for fibrosis (F3) were used (PSC >9.6 kPa, PBC >10.7 kPa; AIH >10.4 kPa). Mayo risk score cut-off 0 differentiated mild vs. moderate-high risk. Values are given as AUC (95% CI). AIH, autoimmune hepatitis; AUROC, area under the receiver operator characteristics curve; BGM, biglycan marker; ELF, enhanced liver fibrosis test; LSM, liver stiffness measurement; Mayo, PSC-specific revised Mayo risk score; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; VICM, citrullinated vimentin.